Oncimmune Holdings Ord 1p

ONC: 118.65 0.00 (0.00%)

Delayed:2016-11-25 18:15:01
Bid Price 117.00 High Price 0.00
Ask Price 120.00 Low Price 0.00
Open Price 118.50 Spread 2.53%
Prev Close 118.50 Volume 0.00

Oncimmune Holdings Ord 1p Share Price Chart

Intraday

Historic – 1 year


Oncimmune Holdings Ord 1p Share Price Information

Name Oncimmune Holdings Ord 1p Epic ONC
Sector Pharmaceuticals & Biotechnology ISIN GB00BYQ94H38
Activites Oncimmune Holdings plc is a leading early cancer detection company, developing and commercialising its proprietary EarlyCDT platform technology. The Group has pioneered the development of tests based on the presence in the blood of autoantibodies against specific tumour associated antigens (TAAs) that have the potential to detect cancer up to 4 years earlier than other methods such as a chest X-ray or Spiral CT (computed tomography) and can be applied to a very wide range of solid tumour types. Oncimmune Limited was incorporated in 2002 as a spin out from the University of Nottingham focusing on the early detection of cancer. Security Type Equity

Key numbers

Latest Share Price (p) 118.50 Net Gearing (%) -77.80
Market Cap (£m) 60.46 Gross Gearing (%) 13.18
Shares in issue (m) 51.02 Debt Ratio 3.90
P/E Ratio 0.00 Debt-to-Equity Ratio 0.27
Divs per share (p) 0.00 Assets / Equity Ratio 1.15
Dividend Yield (%) 0.00 Price to book value 6.21
Dividend Cover 0.00 SROCE (%) -88.94
Earning per share (p) 0.00 EPS Growth (%)
52-week high / low (p) 132.50 / 104.50 DPS Growth (%)

Oncimmune Holdings Ord 1p Broker Views

Date Broker Rec. Price Old target price New target price Notes
08 Nov Beaufort Securities Speculative Buy 118.65 Retains
18 Jul Beaufort Securities Speculative Buy 118.65 Retains
05 Jul Beaufort Securities Speculative Buy 118.65 Initiates/Starts

Oncimmune Holdings Ord 1p Director Deals


Oncimmune Holdings Ord 1p Company News

FLASH: Oncimmune appoints Andrew Millet as CFO






Story provided by StockMarketWire.com

Oncimmune wins CE mark for EarlyCDT-Lung

Oncimmune Holdings has obtained the CE mark for the reagents used in EarlyCDT-Lung, an autoantibody blood test that can detect cancer up to four years earlier than other methods.

The CE mark certifies that the reagents used in EarlyCDT-Lung meet the strict EU standards of manufacturing and quality control dictated by the In Vitro Diagnostics Medical Devices Directive 98/79/EC (IVD Directive).






Story provided by StockMarketWire.com

FLASH: Oncimmune wins CE mark for EarlyCDT-Lung






Story provided by StockMarketWire.com

Oncimmune Holdings notes research agreements

Oncimmune Holdings has signed research agreements with Egybiotech, a private research company with a broad research portfolio in the areas of cancer research, and Aarhus University Hospital (“Aarhus”), Denmark.

Under these agreements, Egybiotech and Aarhus provide Oncimmune with prospectively collected blood samples and associated clinical data on each patient in order to further clinically validate the Company’s EarlyCDT platform technology in liver and ovarian cancer, respectively.

Oncimmune will use the samples to validate panels of autoantibodies as diagnostic tests capable of distinguishing between malignant and non-malignant liver and ovarian diseases, particularly at an early stage.






Story provided by StockMarketWire.com

FLASH: Oncimmune Holdings notes research agreements






Story provided by StockMarketWire.com